543 related articles for article (PubMed ID: 25200615)
1. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
Brandenburg VM; Kleber ME; Vervloet MG; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
Atherosclerosis; 2014 Nov; 237(1):53-9. PubMed ID: 25200615
[TBL] [Abstract][Full Text] [Related]
2. Soluble klotho and mortality: the Ludwigshafen Risk and Cardiovascular Health Study.
Brandenburg VM; Kleber ME; Vervloet MG; Larsson TE; Tomaschitz A; Pilz S; Stojakovic T; Delgado G; Grammer TB; Marx N; März W; Scharnagl H
Atherosclerosis; 2015 Oct; 242(2):483-9. PubMed ID: 26298739
[TBL] [Abstract][Full Text] [Related]
3. Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.
Nakano C; Hamano T; Fujii N; Obi Y; Matsui I; Tomida K; Mikami S; Inoue K; Shimomura A; Nagasawa Y; Okada N; Tsubakihara Y; Rakugi H; Isaka Y
Bone; 2012 Jun; 50(6):1266-74. PubMed ID: 22425694
[TBL] [Abstract][Full Text] [Related]
4. Parathyroid hormone level is associated with mortality and cardiovascular events in patients undergoing coronary angiography.
Pilz S; Tomaschitz A; Drechsler C; Ritz E; Boehm BO; Grammer TB; März W
Eur Heart J; 2010 Jul; 31(13):1591-8. PubMed ID: 20439261
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum fibroblast growth factor-23 level and mortality in chronic hemodialysis patients.
Sugimoto H; Ogawa T; Iwabuchi Y; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):99-106. PubMed ID: 23355029
[TBL] [Abstract][Full Text] [Related]
6. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients.
Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G
Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs).
Westerberg PA; Tivesten Å; Karlsson MK; Mellström D; Orwoll E; Ohlsson C; Larsson TE; Linde T; Ljunggren Ö
BMC Nephrol; 2013 Apr; 14():85. PubMed ID: 23587028
[TBL] [Abstract][Full Text] [Related]
8. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community.
Ärnlöv J; Carlsson AC; Sundström J; Ingelsson E; Larsson A; Lind L; Larsson TE
Kidney Int; 2013 Jan; 83(1):160-6. PubMed ID: 22951890
[TBL] [Abstract][Full Text] [Related]
9. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?
Nowak A; Artunc F; Serra AL; Pollock E; Krayenbühl PA; Müller C; Friedrich B
Kidney Blood Press Res; 2015; 40(3):266-76. PubMed ID: 25997652
[TBL] [Abstract][Full Text] [Related]
11. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
12. Role of fibroblast growth factor 23 (FGF23) in the metabolism of phosphorus and calcium immediately after kidney transplantation.
Sánchez Fructuoso AI; Maestro ML; Calvo N; De La Orden V; Pérez Flores I; Vidaurreta M; Valero R; Fernández-Pérez C; Barrientos A
Transplant Proc; 2012 Nov; 44(9):2551-4. PubMed ID: 23146451
[TBL] [Abstract][Full Text] [Related]
13. Potential Predictors of Plasma Fibroblast Growth Factor 23 Concentrations: Cross-Sectional Analysis in the EPIC-Germany Study.
di Giuseppe R; Kühn T; Hirche F; Buijsse B; Dierkes J; Fritsche A; Kaaks R; Boeing H; Stangl GI; Weikert C
PLoS One; 2015; 10(7):e0133580. PubMed ID: 26193703
[TBL] [Abstract][Full Text] [Related]
14. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
[TBL] [Abstract][Full Text] [Related]
15. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
Moe SM; Chertow GM; Parfrey PS; Kubo Y; Block GA; Correa-Rotter R; Drüeke TB; Herzog CA; London GM; Mahaffey KW; Wheeler DC; Stolina M; Dehmel B; Goodman WG; Floege J;
Circulation; 2015 Jul; 132(1):27-39. PubMed ID: 26059012
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.
Cancela AL; Oliveira RB; Graciolli FG; dos Reis LM; Barreto F; Barreto DV; Cuppari L; Jorgetti V; Carvalho AB; Canziani ME; Moysés RM
Nephron Clin Pract; 2011; 117(1):c74-82. PubMed ID: 20689328
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men.
Marsell R; Grundberg E; Krajisnik T; Mallmin H; Karlsson M; Mellström D; Orwoll E; Ohlsson C; Jonsson KB; Ljunggren O; Larsson TE
Eur J Endocrinol; 2008 Jan; 158(1):125-9. PubMed ID: 18166826
[TBL] [Abstract][Full Text] [Related]
18. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals.
Mirza MA; Alsiö J; Hammarstedt A; Erben RG; Michaëlsson K; Tivesten A; Marsell R; Orwoll E; Karlsson MK; Ljunggren O; Mellström D; Lind L; Ohlsson C; Larsson TE
Arterioscler Thromb Vasc Biol; 2011 Jan; 31(1):219-27. PubMed ID: 20966399
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
[TBL] [Abstract][Full Text] [Related]
20. Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.
Asamiya Y; Yajima A; Shimizu S; Otsubo S; Tsuchiya K; Nitta K
Osteoporos Int; 2015 Mar; 26(3):1017-28. PubMed ID: 25366373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
